Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICX-RHY-013 versus placebo for dystrophic epidermolysis bullosa lesions
ISRCTN67757229Phase 2Completed
- Sponsor
- Intercytex Group
- Start
- Jan 2011
- Modality
- Tissue Cells → Other Cell Types → Cell Therapies
01
Overview
Phase 2, randomised trial of ICX-RHY-013 in dystrophic epidermolysis bullosa (DEB), sponsored by Intercytex Group. Primary endpoint: Time to wound closure. Started Jan 2011; status: completed.
02
Drugs
ICX-RHY-013
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on ISRCTN67757229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN67757229.